Key Drivers
- Rising Debt
- Cash Burn
- Negative Equity
AIAI Summary
IBRX has commercially validated ANKTIVA's demand, but its investment case now depends on sales and label expansions scaling fast enough to offset severe cash burn, $1.23B of debt, and likely dilution—making regulatory execution and financing risk more important than revenue growth alone.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Rising Debt
- •Cash Burn
- •Negative Equity
IBRX's strong near-term liquidity is outweighed by rising debt, negative equity, persistent losses, cash burn, and an elevated sales multiple, suggesting high financing and execution risk.
Price Behavior
Key Price Behavior Insights:
- •Volatile rebound
- •Near resistance
- •Support holding
IBRX rebounded 9% last month to $8.48, but remains volatile below $8.46–$8.48 resistance, with support at $7.90–$8.00.
Uneven reversals between $7.90 and $8.40
Sentiment & News
Key News Insights:
- •Analyst optimism
- •Institutional buying
- •Legal overhang
ImmunityBio's momentum, bullish analyst targets and growing institutional stakes support upside, though earnings revisions and class-action risk warrant caution.
Positive catalysts may support IBRX shares, but near-term volatility remains likely
Similar Companies in Healthcare
Other companies in the same sector with AI ratings